Shanghai Shenqi Pharmaceutical Investment Management Co Ltd Relative Valuation - Shanghai Shenqi Pharmaceutical Investment Management Co Ltd

Watchlist Manager

Watchlist

Price: 6.35 CNY -1.24% Market Closed

Market Cap: ¥3.4B

Relative Value

The Relative Value of one Shanghai Shenqi Pharmaceutical Investment Management Co Ltd stock under the Base Case scenario is hidden CNY. Compared to the current market price of 6.35 CNY, Shanghai Shenqi Pharmaceutical Investment Management Co Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

What is Relative Valuation?

How is Relative Value calculated?

Shanghai Shenqi Pharmaceutical Investment Management Co Ltd Relative Value

Show

Worst Case

Base Case

Best Case

Valuation Multiples

View Details

Multiples Across Competitors

All Multiples

P/S

P/E

EV/EBITDA

EV/EBIT

Forward Multiples

			Market Cap	P/S	P/E	EV/EBITDA	EV/EBIT
CN		Shanghai Shenqi Pharmaceutical Investment Management Co Ltd SSE:600613	3.4B CNY	1.8	54.4	31.4	31.4
US		Eli Lilly and Co NYSE:LLY	923.3B USD	14.2	44.7	30.2	32.2
US		Johnson & Johnson NYSE:JNJ	582.8B USD	6.2	21.7	15.1	18.6
CH		Roche Holding AG SIX:ROG	253.4B CHF	4.1	19.6	11.6	13.1
UK		AstraZeneca PLC LSE:AZN	223.5B GBP	5.1	29.3	16.2	22.9
CH		Novartis AG SIX:NOVN	231.8B CHF	5.3	21.4	13.2	17
US		Merck & Co Inc NYSE:MRK	286.8B USD	4.4	15.7	9.8	11.9
IE	E	Endo International PLC LSE:0Y5F	218B USD	94	-74.6	344.9	865
DK		Novo Nordisk A/S CSE:NOVO B	1.1T DKK	3.6	10.8	8	9.4
US		Pfizer Inc NYSE:PFE	152.7B USD	2.4	19.7	7.6	10.1
US		Bristol-Myers Squibb Co NYSE:BMY	118.7B USD	2.5	16.8	7.1	8.8

				Revenue Growth	P/S to Growth
CN		Shanghai Shenqi Pharmaceutical Investment Management Co Ltd SSE:600613	Average P/S: 13.1 1.8	N/A	N/A
US		Eli Lilly and Co NYSE:LLY	14.2	19%	0.7
US		Johnson & Johnson NYSE:JNJ	6.2	6%	1
CH		Roche Holding AG SIX:ROG	4.1	4%	1
UK		AstraZeneca PLC LSE:AZN	5.1	7%	0.7
CH		Novartis AG SIX:NOVN	5.3	5%	1.1
US		Merck & Co Inc NYSE:MRK	4.4	5%	0.9
IE	E	Endo International PLC LSE:0Y5F	94	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	3.6	2%	1.8
US		Pfizer Inc NYSE:PFE	2.4	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	2.5	-5%	N/A

				Earnings Growth	PEG
CN		Shanghai Shenqi Pharmaceutical Investment Management Co Ltd SSE:600613	Average P/E: 25.4 54.4	N/A	N/A
US		Eli Lilly and Co NYSE:LLY	44.7	32%	1.4
US		Johnson & Johnson NYSE:JNJ	21.7	7%	3.1
CH		Roche Holding AG SIX:ROG	19.6	14%	1.4
UK		AstraZeneca PLC LSE:AZN	29.3	26%	1.1
CH		Novartis AG SIX:NOVN	21.4	14%	1.5
US		Merck & Co Inc NYSE:MRK	15.7	14%	1.1
IE	E	Endo International PLC LSE:0Y5F	Negative Multiple: -74.6	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	10.8	1%	10.8
US		Pfizer Inc NYSE:PFE	19.7	22%	0.9
US		Bristol-Myers Squibb Co NYSE:BMY	16.8	16%	1.1

				EBITDA Growth	EV/EBITDA to Growth
CN		Shanghai Shenqi Pharmaceutical Investment Management Co Ltd SSE:600613	Average EV/EBITDA: 45 31.4	N/A	N/A
US		Eli Lilly and Co NYSE:LLY	30.2	22%	1.4
US		Johnson & Johnson NYSE:JNJ	15.1	2%	7.6
CH		Roche Holding AG SIX:ROG	11.6	6%	1.9
UK		AstraZeneca PLC LSE:AZN	16.2	13%	1.2
CH		Novartis AG SIX:NOVN	13.2	5%	2.6
US		Merck & Co Inc NYSE:MRK	9.8	3%	3.3
IE	E	Endo International PLC LSE:0Y5F	344.9	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	8	1%	8
US		Pfizer Inc NYSE:PFE	7.6	-9%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	7.1	-10%	N/A

				EBIT Growth	EV/EBIT to Growth
CN		Shanghai Shenqi Pharmaceutical Investment Management Co Ltd SSE:600613	Average EV/EBIT: 94.6 31.4	N/A	N/A
US		Eli Lilly and Co NYSE:LLY	32.2	22%	1.5
US		Johnson & Johnson NYSE:JNJ	18.6	7%	2.7
CH		Roche Holding AG SIX:ROG	13.1	5%	2.6
UK		AstraZeneca PLC LSE:AZN	22.9	21%	1.1
CH		Novartis AG SIX:NOVN	17	9%	1.9
US		Merck & Co Inc NYSE:MRK	11.9	6%	2
IE	E	Endo International PLC LSE:0Y5F	865	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	9.4	3%	3.1
US		Pfizer Inc NYSE:PFE	10.1	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	8.8	-7%	N/A

Shanghai Shenqi Pharmaceutical Investment Management Co Ltd
SSE:600613

Relative Value

Valuation Multiples

Multiples Across Competitors

Competitors Multiples
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd Competitors

See Also

Company

Help

Tools

Stocks

Shanghai Shenqi Pharmaceutical Investment Management Co Ltd SSE:600613

Relative Value

Valuation Multiples

Multiples Across Competitors

Competitors Multiples Shanghai Shenqi Pharmaceutical Investment Management Co Ltd Competitors

See Also

Company

Help

Tools

Stocks

Shanghai Shenqi Pharmaceutical Investment Management Co Ltd
SSE:600613

Competitors Multiples
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd Competitors